CD9 immunohistochemical staining of breast carcinoma: unlikely to provide useful prognostic information for routine use
CD9 immunohistochemical staining of breast carcinoma: unlikely to provide useful prognostic information for routine use
复制标题
DOI：
10.1046/j.1365-2559.2001.01296.x
复制
发表时间：
2001-12-01
期刊：
影响因子：
6.4
通讯作者：
Shousha, S
中科院分区：
文献类型：
--
作者：
Jamil, F;Peston, D;Shousha, S
目的：CD9 是一种细胞膜糖蛋白，存在于多种肿瘤细胞中，被认为可以调节细胞运动并可能调节细胞生长。据报道，CD9的缺失与乳腺癌的侵袭性增加有关，但目前还没有关于CD9在正常和异常乳腺组织中分布的详细研究。本研究旨在研究 CD9 在各种乳腺活检组织中的分布，包括正常、良性和恶性病例，并评估其作为乳腺癌预后标志物的有用性。 方法和结果：对来自女性和男性患者的 113 例乳腺活检切片进行了检查，其中包括 10 例正常病例、23 例良性病例和 80 例恶性病例。单克隆抗体 CD9（Novacastra Ltd，Newcastleupon-Tyne，英国）与抗生物素蛋白-生物素复合物免疫过氧化物酶技术一起使用。使用 3+、2+、1+ 和阴性四级系统对结果进行半定量评估。所有正常和良性上皮细胞均被强烈染色（3+）。在女性乳腺癌中，40% 为 3+，49% 为 2+，11% 为 1+。两例男性乳腺癌的评分均为 3+。对于女性乳腺癌，结果与肿瘤分级、是否存在淋巴结转移以及雌激素和孕激素受体状态相关。没有发现任何这些参数具有显着的统计相关性。然后我们检查了 11 个腋窝淋巴结，这些淋巴结来自上述一些病例的转移。其中 3 例 CD9 评分为 3+，7 例为 2+，1 例为 1+。所有 11 例中的转移性肿瘤均被强染色 (3+)。结论：CD9 免疫染色不太可能为临床目的提供任何有用的附加预后信息。
Aims: CD9, a cell membrane glycoprotein, is found in a variety of tumour cells and is believed to regulate cell motility and possibly cell growth. It has been reported that the absence of CD9 is associated with increased aggressiveness of breast carcinoma, but no detailed studies of the distribution of CD9 in normal and abnormal breast tissue are available. This investigation was aimed at studying the distribution of CD9 in a wide variety of breast biopsies including normal, benign, and malignant cases, and assessing its usefulness as a prognostic marker in breast cancer.Methods and results: Sections of 113 breast biopsies from female and male patients including 10 normal, 23 benign, and 80 malignant cases were examined. The monoclonal antibody CD9 (Novacastra Ltd, Newcastleupon-Tyne, UK) was used with the avidin-biotin complex immunoperoxidase technique. The results were assessed semiquantitatively using a four scale system of 3+, 2+, 1+ and negative. All normal and benign epithelial cells were strongly stained (3+). In female breast carcinomas, 40% were 3+, 49% were 2+, and 11% were 1+. Both cases of male breast carcinomas scored 3+. For female breast cancers, the results were then correlated to tumour grade, the presence or absence of lymph node metastases, and oestrogen and progesterone receptor status. No significant statistical correlation was found with any of these parameters. We then examined 11 axillary lymph nodes with metastases from some of the above cases. Three of these cases had a CD9 score of 3+, seven were 2+, and one was 1+. The metastatic tumours in all 11 cases were strongly stained (3+).Conclusions: Immunostaining for CD9 is unlikely to provide any useful additional prognostic information for clinical purposes.